Aldeyra Therapeutics, Inc.
ALDXNASDAQHealthcare● Active
$1.74
+$0.11(+6.86%)
Market Cap$105067236
P/E Ratio—
52W High$6.175
52W Low$1.07
Aldeyra Therapeutics, Inc. (ALDX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALDX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.06
Est. -$0.13 · +53.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
ALDX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.11 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.13 | -$0.06 | +53.9% | — | — | — |
| ▲ Q1 FY2026 | Feb 27, 2026 | -$0.14 | -$0.11 | +21.4% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.17 | -$0.13 | +23.5% | — | $0.02B | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.21 | -$0.16 | +23.8% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.25 | -$0.17 | +32.0% | — | $-0.00B | — |
| ▼ Q1 FY2025 | Feb 28, 2025 | -$0.25 | -$0.27 | -8.0% | $0.00B | — | — |
| — Q4 FY2024 | Nov 7, 2024 | -$0.25 | -$0.25 | +0.0% | — | $0.03B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.13
EPS Surpr.
+53.9%
Revenue
—
Q1 FY2026
Feb 27, 2026Beat
EPS Actual
-$0.11
EPS Est.
-$0.14
EPS Surpr.
+21.4%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.17
EPS Surpr.
+23.5%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.21
EPS Surpr.
+23.8%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.17
EPS Est.
-$0.25
EPS Surpr.
+32.0%
Revenue
—
Q1 FY2025
Feb 28, 2025Miss
EPS Actual
-$0.27
EPS Est.
-$0.25
EPS Surpr.
-8.0%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024
EPS Actual
-$0.25
EPS Est.
-$0.25
EPS Surpr.
+0.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q3 FY2026 | $-0.10 | $-0.10 | $-0.10 | 2 |
| Q2 FY2026 | $-0.10 | $-0.10 | $-0.10 | 2 |
| Q1 FY2026 | $-0.10 | $-0.10 | $-0.10 | 2 |
| Q4 FY2025 | $-0.14 | $-0.14 | $-0.14 | 3 |
| Q3 FY2025 | $-0.14 | $-0.14 | $-0.13 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-2.0B | $-2.0B | $-2.0B | 1 |
| Q3 FY2026 | $-0.0B | $-0.0B | $-0.0B | 2 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +53.9% | $1.74 | $1.73 | -0.57% |
| ▲ Q1 FY2026 | Feb 27, 2026 | +21.4% | $5.50 | $5.46 | -0.73% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +23.5% | $4.92 | $4.93 | +0.20% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +23.8% | $5.22 | $5.17 | -0.96% |
| ▲ Q2 FY2025 | May 14, 2025 | +32.0% | $2.08 | $2.17 | +4.33% |
| ▼ Q1 FY2025 | Feb 28, 2025 | -8.0% | $6.34 | $5.11 | -19.40% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +0.0% | $5.40 | $5.34 | -1.11% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -100.0% | $3.94 | $3.71 | -5.84% |
Q2 FY2026-0.57%
Report Date
May 7, 2026
EPS Beat/Miss
+53.9%
Price Before
$1.74
Price After
$1.73
Q1 FY2026-0.73%
Report Date
Feb 27, 2026
EPS Beat/Miss
+21.4%
Price Before
$5.50
Price After
$5.46
Q4 FY2025+0.20%
Report Date
Nov 5, 2025
EPS Beat/Miss
+23.5%
Price Before
$4.92
Price After
$4.93
Q3 FY2025-0.96%
Report Date
Aug 7, 2025
EPS Beat/Miss
+23.8%
Price Before
$5.22
Price After
$5.17
Q2 FY2025+4.33%
Report Date
May 14, 2025
EPS Beat/Miss
+32.0%
Price Before
$2.08
Price After
$2.17
Q1 FY2025-19.40%
Report Date
Feb 28, 2025
EPS Beat/Miss
-8.0%
Price Before
$6.34
Price After
$5.11
Q4 FY2024-1.11%
Report Date
Nov 7, 2024
EPS Beat/Miss
+0.0%
Price Before
$5.40
Price After
$5.34
Q3 FY2024-5.84%
Report Date
Aug 1, 2024
EPS Beat/Miss
-100.0%
Price Before
$3.94
Price After
$3.71
Avg Beat Reaction+0.19%
Avg Miss Reaction-12.62%
Beat Rate6 / 8 quarters
Largest Move-19.40% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALDX ends December
Aldeyra Therapeutics, Inc. (ALDX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.06 — beating the analyst consensus of $-0.13 by +53.9%. ALDX has beaten EPS estimates for 5 consecutive quarters. The next ALDX earnings date is expected around September 1, 2026.
Each quarter, investors track ALDX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALDX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALDX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALDX earnings · 5 questionsAldeyra Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ALDX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALDX historically reports after market close (AMC).
ALDX earnings datewhen is ALDX earningsALDX next earnings datewhen does ALDX report earningsALDX earnings calendar
▸ Source: FMP · Aldeyra Therapeutics, Inc. SEC filings · US GAAP · Aldeyra Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026